GGrantIndex
← Leaderboards

Murugaiyan Gopal

Brigham And Women'S Hospital

$7,662,393
Attributed
$7,662,393
Total exposure
6
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.7M · FY201725
$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$7,662,393 · 6

By mechanism

R01$6,753,733 · 4
R21$908,660 · 2

Top collaborators

No co-investigators on record.

Most similar at Brigham And Women'S Hospital

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Inflammatory

Research focus

InflammatoryIn VitroIn VivoPathway InteractionsInflammationInterestImmunePathogenicityResponseCd4 Positive T LymphocytesCellsRegulatory T-LymphocyteT-LymphocyteMediatingAnimal ModelCytokinePreventPathogenesisTissuesNovel TherapeuticsInterleukin-23MicrornasFunctional DisorderHelper-Inducer T-Lymphocyte

Grant awards (20)

Development of novel PD1 agonist therapeutic strategies for inflammatory bowel disease$463,650
R01 · FY2025 · DK · contact PI
MicroRNA control of tumor-promoting inflammation in colon cancer$386,331
R01 · FY2025 · CA · contact PI
Development of novel PD1 agonist therapeutic strategies for inflammatory bowel disease$463,650
R01 · FY2024 · DK · contact PI
The pathogenic role of miR-92a in the regulation of T helper cell responses in EAE and MS$422,220
R01 · FY2024 · AI · contact PI
MicroRNA control of tumor-promoting inflammation in colon cancer$367,016
R01 · FY2024 · CA · contact PI
Therapeutic targeting of PD1 signaling in inflammatory bowel disease$255,860
R21 · FY2024 · AI · contact PI
Development of novel PD1 agonist therapeutic strategies for multiple sclerosis$218,220
R21 · FY2024 · AI · contact PI
The pathogenic role of miR-92a in the regulation of T helper cell responses in EAE and MS$422,220
R01 · FY2023 · AI · contact PI
MicroRNA control of tumor-promoting inflammation in colon cancer$378,605
R01 · FY2023 · CA · contact PI
Development of novel PD1 agonist therapeutic strategies for multiple sclerosis$223,470
R21 · FY2023 · AI · contact PI
Therapeutic targeting of PD1 signaling in inflammatory bowel disease$211,110
R21 · FY2023 · AI · contact PI
MicroRNA control of tumor-promoting inflammation in colon cancer$386,331
R01 · FY2022 · CA · contact PI
The pathogenic role of miR-92a in the regulation of T helper cell responses in EAE and MS$286,665
R01 · FY2022 · AI · contact PI
The pathogenic role of miR-92a in the regulation of T helper cell responses in EAE and MS$557,775
R01 · FY2021 · AI · contact PI
MICRORNA CONTROL OF INFLAMMATORY AND REGULATORY T CELLS IN CENTRAL NERVOUS SYSTEM AUTOIMMUNITY$439,410
R01 · FY2021 · AI · contact PI
MICRORNA CONTROL OF INFLAMMATORY AND REGULATORY T CELLS IN CENTRAL NERVOUS SYSTEM AUTOIMMUNITY$439,410
R01 · FY2020 · AI · contact PI
The pathogenic role of miR-92a in the regulation of T helper cell responses in EAE and MS$422,220
R01 · FY2020 · AI · contact PI
MICRORNA CONTROL OF INFLAMMATORY AND REGULATORY T CELLS IN CENTRAL NERVOUS SYSTEM AUTOIMMUNITY$439,410
R01 · FY2019 · AI · contact PI
MICRORNA CONTROL OF INFLAMMATORY AND REGULATORY T CELLS IN CENTRAL NERVOUS SYSTEM AUTOIMMUNITY$439,410
R01 · FY2018 · AI · contact PI
MICRORNA CONTROL OF INFLAMMATORY AND REGULATORY T CELLS IN CENTRAL NERVOUS SYSTEM AUTOIMMUNITY$439,410
R01 · FY2017 · AI · contact PI